A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
复制标题
针对晚期难治性淋巴瘤患者的动力学设计化疗方案。
DOI：
10.1002/mpo.2950040209
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
C. Coltman
中科院分区：
文献类型：
--
作者：
A. Rossof;R. Kerr;H. Braine;C. Coltman
3例霍奇金病患者、8例非霍奇金淋巴瘤患者和1例常规联合化疗难治的慢性淋巴细胞白血病患者接受了一种新的动力学设计的四种药物组合的诱导缓解治疗，该组合由博来霉素、长春新碱、阿霉素和泼尼松组成，并给予首字母缩写“BOAP”。“8名患者既往接受过放疗，其中2名接受过全淋巴结放疗。8例患者（所有3例霍奇金病和5例非霍奇金淋巴瘤）达到完全缓解（73%的淋巴瘤患者）。另外两名非霍奇金淋巴瘤患者持续部分缓解，总体缓解率为91%。毒性导致3名患者治疗中断，另外1名患者可能持续药物相关死亡。本研究与其他研究晚期淋巴瘤的原发或继发联合化疗的研究相比，具有优势。
Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP." Eight patients had prior radiotherapy, included two who had total nodal irradiation. Eight patients (all three with Hodgkin disease and five of eight with non-Hodgkin lymphoma) achieved complete remission (73% of the lymphoma patients). An additional two patients with non-Hodgkin lymphoma sustained partial remissions, for an overall response rate of 91%. Toxicity caused the interruption of therapy in three patients and an additional patient might have sustained a drug-related death. This study compares favorably with other studies investigating primary or secondary combination chemotherapy of advanced lymphomas.